As the 1 mg/kg dose of STN in our study is at the higher end of the spectrum of HMGCRi use by patients with cardiovascular disease, dose relationships as well as differences in lipophilic and non-lipophilic HMGCRi could be explored in these studies prior to planning specific trials with OxPhos- and HMGCR-targeting agents. The gene discussed is HMGCR; the disease is cardiovascular disorder.